Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on June 26, 2026. The report details a material definitive agreement entered into on the same date regarding the supply of smallpox vaccine to the U.S. government.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial value disclosed is the contract modification value of $52.7 million.
Material Changes and Agreements
- Contract Modification: Emergent received Modification No. 15 from the Office of the Assistant Secretary for Preparedness and Response (ASPR).
- Option Exercise: The modification exercises Option Year 7 of the existing 10-year ACAM2000 Contract.
- Value: The modification is valued at $52.7 million.
- Deliverables: Emergent is required to deliver ACAM2000 doses, ancillaries, and diluent replacement lots in June 2026, with any remaining diluent balance due by December 2026.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard qualification that the description of the contract modification is not complete. A press release regarding this agreement was issued on June 29, 2026, and is incorporated by reference.
Key Facts for Investor Verification
- Verify the full text of Modification No. 15 when filed as an exhibit to the next Form 10-Q.
- Confirm the specific volume of ACAM2000 doses and ancillaries included in the $52.7 million valuation.
- Review the press release dated June 29, 2026 (Exhibit 99.1) for additional context on the agreement.
- Monitor the delivery schedule to ensure compliance with the June and December 2026 deadlines.